THP (docetaxel + trastuzumab + pertuzumab)
Checked 2026-09-09
HER2-positive metastatic breast cancer first line, then HP maintenance
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Docetaxel Cytotoxic chemotherapy (taxane) | 75 mg/m² | IV | D1 | |
Trastuzumab Monoclonal antibody (anti-HER2) | 8 mg/kg loading then 6 mg/kg | IV | D1 | |
Pertuzumab Monoclonal antibody (anti-HER2, dimerisation domain) | 840 mg loading then 420 mg | IV | D1 |
Cycles
docetaxel 6 or more; HP until progression
21-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Consider (10-20% FN risk)
Notes
- Median OS 57.1 months; DESTINY-Breast09 (T-DXd + pertuzumab) now competes for first line.
Used in
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Dose-dense AC → T
Node-positive or high-risk early breast cancer, adjuvant or neoadjuvant
every 14 days × 4
TCHP
Stage II-III HER2-positive breast cancer, neoadjuvant
every 21 days × 6
APT (weekly paclitaxel + trastuzumab)
Stage I HER2-positive breast cancer, node-negative, tumour 3 cm or smaller
weekly × 12
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days